Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the
speaker lineup for a “Spotlight Session” the company is hosting at
the Orthopaedic Summit 2019: Evolving Techniques (OSET 2019) annual
meeting in Las Vegas. Scheduled for Thursday, December 12, at 6
p.m. PT in Grand Ballroom 3 at the Bellagio, the session features
John Richmond, M.D., the former chairman of orthopedic surgery at
New England Baptist Hospital, Boston Sports and Shoulder Center,
and Chad Hanson, M.D., president of Desert Orthopaedic Center in
Las Vegas.
Dr. Richmond will kick off the program with a review of the
clinical data supporting ZILRETTA (triamcinolone acetonide
extended-release injectable suspension), an intra-articular
treatment for osteoarthritis knee pain. Dr. Hanson will then join
“Knee to Knee,” a dynamic panel discussion including retired
professional athletes and moderated by NFL player turned
broadcaster Solomon Wilcots.
Mr. Wilcots was a starting defensive back for the Cincinnati
Bengals’ 1988 AFC Championship and Super Bowl XXIII team. He will
lead the panelists in a conversation about their personal
experiences with ZILRETTA. The ZILRETTA patients include:
- Mike Eruzione, Captain, 1980 USA Hockey TeamMr. Eruzione, 65,
is best known as the captain of the 1980 USA national team that
defeated the Soviet Union in the "Miracle on Ice" game in which he
scored the game-winning goal. That goal has become one of the most
played highlights in American sports and was voted the greatest
highlight of all time by ESPN viewers in March 2008. He currently
works with Boston University and as a motivational
speaker.
- Rod Woodson, NFL Hall of Fame MemberMr. Woodson, 54, played in
the NFL for 17 seasons and was inducted into the Pro Football Hall
of Fame in 2009. He had a 10-year stint with the Pittsburgh
Steelers and was a key member of the Baltimore Ravens' Super Bowl
XXXV championship team that beat the New York Giants. He also
played for the San Francisco 49ers and Oakland Raiders. Mr. Woodson
has worked as a broadcaster and coach since his retirement as a
player.
- Chris Dickerson, Retired MLB PlayerMr. Dickerson, 37, played
professional baseball for 15 years and spent seven seasons as a
major league outfielder with the New York Yankees, Cincinnati Reds,
Milwaukee Brewers, Baltimore Orioles and Cleveland Indians. He
retired in 2017 to pursue a career with a sports technology company
and broadcasting work.
“From weekend warriors to active seniors, OA is an
indiscriminate disease that can have a drastic impact on one’s
life,” said Michael Clayman, M.D., President and Chief Executive
Officer. “We are tremendously pleased to partner with this
illustrious group of athletes to call attention to the disease and
raise awareness about the important role ZILRETTA can play in the
management of OA knee pain.”
Physicians attending OSET 2019 can register for the session
online at www.ZILRETTA.com/OSET. Advance registration is strongly
recommended due to limited seating.
The Orthopaedic Summit 2019: Evolving Techniques is the premier
gathering of total joint (knee, hip, shoulder), foot & ankle,
sports medicine, arthroscopic, spine and trauma surgeons, physician
assistants, nurse practitioners, athletic trainers, and physical
and occupational therapists from across the globe. This year’s
summit is set for December 11-14 in Las Vegas. For more information
visit www.orthosummit.com.
Indication and Select Important Safety Information for
ZILRETTA
Indication: ZILRETTA is indicated as an
intra-articular injection for the management of osteoarthritis pain
of the knee. It is not intended for repeat administration.
Contraindication: ZILRETTA is contraindicated
in patients who are hypersensitive to triamcinolone acetonide,
corticosteroids or any components of the product.
Warnings and Precautions:
Intra-articular Use Only: ZILRETTA has not been
evaluated and should not be administered by epidural, intrathecal,
intravenous, intraocular, intramuscular, intradermal, or
subcutaneous routes. ZILRETTA should not be considered safe for
epidural or intrathecal administration.
Serious Neurologic Adverse Reactions with Epidural and
Intrathecal Administration: Serious neurologic events have
been reported following epidural or intrathecal corticosteroid
administration. Corticosteroids are not approved for this use.
Hypersensitivity reactions: Serious reactions
have been reported with triamcinolone acetonide injection.
Institute appropriate care if an anaphylactic reaction occurs.
Joint infection and damage: A marked increase
in joint pain, joint swelling, restricted motion, fever and malaise
may suggest septic arthritis. If this occurs, conduct appropriate
evaluation and if confirmed, institute appropriate antimicrobial
treatment.
Adverse Reactions: The most commonly reported
adverse reactions (incidence ≥1%) in clinical studies included
sinusitis, cough, and contusions.
Please see ZilrettaLabel.com for full Prescribing
Information.
About ZILRETTA
On October 6, 2017, ZILRETTA was approved by the U.S. FDA as the
first and only extended-release intra-articular therapy for
patients confronting osteoarthritis-related knee pain. ZILRETTA
employs proprietary microsphere technology combining triamcinolone
acetonide — a commonly administered, short-acting corticosteroid —
with a poly lactic-co-glycolic acid (PLGA) matrix to provide
extended pain relief. The pivotal Phase 3 trial on which the
approval of ZILRETTA was based showed that ZILRETTA significantly
reduced knee pain for 12 weeks, with some people experiencing pain
relief through Week 16. Learn more at www.zilretta.com.
About Osteoarthritis (OA) of the Knee
OA, also known as degenerative joint disease, affects more than
30 million adults living in the U.S. and accounts for more than
$185 billion in annual expenditures. In 2016, more than 15 million
Americans were diagnosed with OA of the knee and the average age of
physician-diagnosed knee OA has fallen by 16 years, from 72 in the
1990s to 56 in the 2010s. The prevalence of OA is expected to
continue to increase as a result of aging, obesity and sports
injuries. Each year, approximately five million OA patients receive
either an immediate-release corticosteroid or hyaluronic acid
intra-articular injection to manage their knee pain.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical
company focused on the development and commercialization of novel,
local therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, the most common form of
arthritis. The company's core values are focus, ingenuity,
tenacity, transparency and fun. Visit
flexiontherapeutics.com.
Contacts:
Scott YoungFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Scott StachowiakRusso Partners Sports-Health AllianceT: (646)
942-5630sstachowiak@russopartnersllc.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/e7defc64-a02d-4cc9-98c7-b71fc9f1263a
https://www.globenewswire.com/NewsRoom/AttachmentNg/381257db-3f0f-4042-9c9e-47e30588e192
https://www.globenewswire.com/NewsRoom/AttachmentNg/687d5fea-6fd4-4ecd-aa11-594fbf5c9744
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Sep 2023 to Sep 2024